Dendritic Cell Activator Metabolite for Low-Side-Effect Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immune-activating substances derived from natural products often cause severe side effects, and there is a need for a dendritic cell activator that can enhance the acquired immune system effectively against cancer and infectious diseases without such drawbacks.
Innovation Solution
A dendritic cell activator containing 5-(3,5-dihydroxyphenyl)-γ-valerolactone, derived from intestinal bacterial metabolites of catechins, promotes the differentiation and activation of conventional dendritic cells (cDCs), enhancing cellular immunity by inducing CD8+ T cells into cytotoxic T cells and inhibiting Th2 cell differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing immune-activating substances derived from natural products are used, then immune activation function is improved, but side effects occur frequently and severely
Solution Approach 1:
The patent transforms catechins through controlled bacterial fermentation to produce a specific metabolite (5-(3,5-dihydroxyphenyl)-γ-valerolactone). This parameter change in molecular structure fundamentally alters the compound's biological properties, achieving potent dendritic cell activation while eliminating the severe side effects associated with conventional immune-activating substances.
Solution Approach 2:
The patent introduces intestinal bacteria as an intermediary to transform catechins into the active metabolite. This intermediary process naturally occurs in the gut, allowing the compound to be safely ingested and activated only where needed, avoiding the direct administration of harsh immune stimulants that cause side effects.
2Reliability
If conventional immune-activating substances are administered, then immune response is enhanced, but Th2 cell differentiation is inhibited which reduces cellular immunity
Solution Approach 1:
The metabolite exhibits selective immunomodulatory effects, locally enhancing dendritic cell activation and Th1 cell differentiation while leaving other immune pathways unaffected. This localized action at the dendritic cell level ensures enhanced cellular immunity without the broad immunosuppression caused by conventional substances.
Solution Approach 2:
Instead of directly stimulating T cells or other immune components, the patent inverts the approach by targeting dendritic cells upstream in the immune activation pathway. By activating dendritic cells, the compound indirectly and appropriately directs T cell differentiation toward Th1 and cytotoxic phenotypes, avoiding the harmful inhibition of cellular immunity.
Data Source
Figure 1
Figure 2(A)~2(C)
Figure 3(A)~3(B)
AI summary
Provided is a dendritic cell activator that contains, as an active ingredient, a component derived from a natural product which has been eaten for many years and the safety of which has been empirically confirmed, and that is used for inducing or promoting an acquired immune response effective against cancer or infectious disease. Specifically provided are: a dendritic cell activator containing, as an active ingredient, 5-(3,5-dihydroxyphenyl)-y-valerolactone represented by formula (I); and a medicine, a supplement, and a food or beverage each containing the compound represented by formula (I) as an active ingredient. [The configuration of the wavy line may be either R-form or S-form.]